|Allen Cato, MD, PhD – Principal
Dr. Cato is a principal and cofounder of Cato BioVentures. He also is a cofounder of Cato Research and serves as its president, CEO, and a director. Dr. Cato serves as a member of the clinical advisory board of VistaGen Therapeutics and in senior management or director roles for several of our portfolio companies, past and present, including but not limited to, Advanced Pain Remedies, Cancer Advances, Hemodynamic Therapeutics and Nutritional Restart Pharmaceuticals. He has 40 years’ experience in clinical research and new drug development and has directed or participated in the development of more than 100 INDs and NDAs
|Lynda Sutton, BS – Principal
Ms. Sutton is a principal and cofounder of Cato BioVentures. She also is a cofounder of Cato Research and serves as a director and its’ chief regulatory officer. Ms. Sutton serves in senior management and director roles for several of our portfolio companies, past and present, including but not limited to, Advanced Pain Remedies, Cancer Advances, Hemodynamic Therapeutics and Nutritional Restart Pharmaceuticals. She has more than 30 years’ experience in the pharmaceutical industry, with special expertise in regulatory strategies and regulatory compliance requirements. She has coordinated activities in various disciplines (e.g., toxicology, pharmacology, pharmacokinetics, analytical and pharmaceutical development, and clinical research), has been involved in the development of new clinical entities, has overseen the preparation of FDA meeting submissions, and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied.
|Daniel Pharand, CA – Principal
Mr. Pharand is a chartered accountant with more than 25 years’ experience in the pharmaceutical, biotechnology, and life sciences industries, where he has a proven track record as a portfolio manager. He serves as a principal of Cato BioVentures and as chief financial officer of Cato Research. Mr. Pharand was the CFO of Pharmacia Canada and of Pharmacia KK (Japan). He subsequently became an entrepreneur with a successful Canadian distribution company of innovative pedicular screw systems in orthopedic therapies. Mr. Pharand later was involved, as a portfolio manager, in a biotech venture with Innovatech Grand Montreal. Mr. Pharand has also acted as a director, including holding seats on various board committees for more than 30 publicly traded or life sciences corporations.
|Michael Cato, MS, RAC – Vice President
Mr. Cato serves as Vice President for Cato BioVentures. He also serves as a Vice President of Quality Assurance at Cato Research. Mr. Cato helps guide the integration of the corporate strategies of Cato Research and Cato BioVentures and is active in the licensing of select portfolio technologies. He has nearly 20 years’ experience in research and management in the area of material sciences, 8 of which was at Michelin, where he was part of the senior management focusing on quality assurance. Mr. Cato obtained his M.S. from North Carolina State University in the Department of Textile Engineering, Chemistry, and Science and is regulatory affairs certified by the Regulatory Affairs Professionals Society.
|Jo Cato, PhD – Vice President
Dr. Jo Cato serves a a Vice President for Cato BioVentures. He also serves as the Managing Director of Cato Research’s San Diego and South San Francisco offices. Dr. Cato has nearly 20 years experience in drug development, with expertise in drug metabolism and mathematical modeling, clinical pharmacokinetic study design, data analysis and reporting, preclinical pharmacokinetics, and toxicokinetics. He served as a pharmacokineticist for both Abbott Laboratories and Ligand Pharmaceuticals prior to joining the Cato team.
|Linda Markus Daniels, JD, MA – Chief Legal Officer
Linda Markus Daniels serves as Chief Legal Officer for Cato BioVentures and Cato Research. Prior to joining the Cato team, she was a founder and principal of Daniels & Daniels, P.A., the first resident law firm in Research Triangle Park, North Carolina, where she concentrated her practice in the representation of entrepreneurial, technology-based, and international businesses and their investors. Ms. Daniels received her undergraduate degree with honors in public policy from Duke University and then received an M.A. with distinction in International Economics from the Johns Hopkins School of Advanced International Studies. After working as an international and regulatory economic analyst for 3 years, she returned to Duke University School of Law where she earned a J.D. and served as an editor of the Duke Law Journal.